Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BCHP | 37.56 | 0.32 | +0.86% |
| Principal Focused Blue Chip ETF (BCHP) | |||
| BMED | 36.28 | 0.18 | +0.49% |
| iShares Health Innovation Active ETF (BMED) | |||
| CGGR | 45.67 | 0.21 | +0.46% |
| Capital Group Growth ETF (CGGR) | |||
| AOK | 40.46 | -0.12 | -0.30% |
| iShares Core 30/70 Conservative Allocation ETF (AOK) | |||
| EFAD | 45.73 | -0.44 | -0.95% |
| ProShares MSCI EAFE Dividend Growers ETF (EFAD) | |||
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.
| Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
|---|---|---|---|---|
| MDGL | 100% | -8.08% | ||
| ALXO - MDGL | 56% Loosely correlated | -5.84% | ||
| IPHA - MDGL | 44% Loosely correlated | -4.32% | ||
| LCTX - MDGL | 43% Loosely correlated | N/A | ||
| CVM - MDGL | 43% Loosely correlated | +7.63% | ||
| VOR - MDGL | 42% Loosely correlated | +3.17% | ||
More | ||||
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MDGL entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.484) is normal, around the industry mean (3.051). P/E Ratio (-28.329) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.